Screener
Royalty Pharma RPRX EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on the most recent quarter.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's EV / EBITDA?
- Royalty Pharma (RPRX) reported EV / EBITDA of 13.9× in Q4 2024.
- How has Royalty Pharma's EV / EBITDA changed year-over-year?
- Royalty Pharma's EV / EBITDA increased by 14.3% year-over-year, from 12.2× to 13.9×.
- What is the long-term trend for Royalty Pharma's EV / EBITDA?
- Over 3 years (2020 to 2024), Royalty Pharma's EV / EBITDA has grown at a -5.0% compound annual growth rate (CAGR), from 16.3× to 13.9×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Royalty Pharma's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude